Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
The role of diabetic blood products on post-transfusion outcomes and HbA1c levels: An in-vitro study
FY 2023-24
Summary
Diabetes mellitus, encompassing both type 1 and type 2, affects over 400 million people worldwide. It is recognized as the excess of sugars or glucose in the body, which in turn can attach to proteins in the body. To diagnose diabetes, doctors often use a measure called glycated hemoglobin (HbA1c), with levels greater than or equal to 6.4% indicating diabetes. Hemoglobin is a protein responsible for delivering oxygen to tissues and organs, however, when coated in sugars, it becomes ineffective at oxygen delivery. Blood transfusions can be used to improve oxygen delivery. Blood transfusions use stored red blood cells (RBC) to increase hemoglobin which improves oxygen delivery. Currently, blood products are stored in high glucose solutions, increasing the HbA1c in a donated blood product. Furthermore, blood donations from diabetic donors also have increased HbA1c levels. Transfusions of such products can affect HbA1c measurements in recipients post-transfusion resulting in improper diagnosis of diabetes. Research findings on this issue have been contradictory. As of recent, diabetic donors, type 1 and type 2, have been able to donate blood at Canadian Blood Services. Our study hopes to understand the impact of blood transfusions on HbA1c levels after transfusions. We will examine how diabetic blood products influence HbA1c in both diabetic and non-diabetic recipients, compared to those receiving non-diabetic blood products. We hope to study these changes using an in-vitro transfusion model where the blood will be sampled at various time points after transfusion to measure HbA1c levels. This will help us understand the impact of blood transfusion HbA1c levels and help healthcare workers better interpret HbA1c levels in transfused patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506250
Name
Phan Celina B
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of diabetic blood products on post-transfusion outcomes and HbA1c levels: An in-vitro study
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anemia; Blood Banking; Blood Products; Diabetes Mellitus; Donor Factors; Hba1c; Hematology; Sickle Cell Disease; Transfusion Medicine; Transfusion-Related Immune Modulation
Abstract
Diabetes mellitus, encompassing both type 1 and type 2, affects over 400 million people worldwide. It is recognized as the excess of sugars or glucose in the body, which in turn can attach to proteins in the body. To diagnose diabetes, doctors often use a measure called glycated hemoglobin (HbA1c), with levels greater than or equal to 6.4% indicating diabetes. Hemoglobin is a protein responsible for delivering oxygen to tissues and organs, however, when coated in sugars, it becomes ineffective at oxygen delivery. Blood transfusions can be used to improve oxygen delivery. Blood transfusions use stored red blood cells (RBC) to increase hemoglobin which improves oxygen delivery. Currently, blood products are stored in high glucose solutions, increasing the HbA1c in a donated blood product. Furthermore, blood donations from diabetic donors also have increased HbA1c levels. Transfusions of such products can affect HbA1c measurements in recipients post-transfusion resulting in improper diagnosis of diabetes. Research findings on this issue have been contradictory. As of recent, diabetic donors, type 1 and type 2, have been able to donate blood at Canadian Blood Services. Our study hopes to understand the impact of blood transfusions on HbA1c levels after transfusions. We will examine how diabetic blood products influence HbA1c in both diabetic and non-diabetic recipients, compared to those receiving non-diabetic blood products. We hope to study these changes using an in-vitro transfusion model where the blood will be sampled at various time points after transfusion to measure HbA1c levels. This will help us understand the impact of blood transfusion HbA1c levels and help healthcare workers better interpret HbA1c levels in transfused patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Phan, Celina B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~